Related Experiment Video

Updated: Feb 22, 2026

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
09:37

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation

Published on: March 15, 2018

14.5K

Bispecific Antibody Binding To RANKL and Osteonectin with Enhanced Localization to the Bone

Jou-Han Chen1, Chun Yu Lin1, Yi-Chun Maria Chen1

  • 1Immunwork, Inc. , Taipei 115, Taiwan.

Molecular Pharmaceutics
|September 29, 2017
PubMed

Insights

Researchers engineered denosumab (Dmab) to target bone-specific osteonectin, creating a bispecific antibody (Dmab-FvOn). This enhanced Dmab distribution within bone tissue, potentially improving treatments for bone destruction and related conditions.

Area of Science:

  • Biotechnology
  • Immunology
  • Oncology

Background:

  • Denosumab (Dmab), an anti-RANKL antibody, treats bone destruction but shows limited efficacy in some patients.
  • Ineffective Dmab distribution in the bone microenvironment contributes to suboptimal therapeutic outcomes.

Purpose of the Study:

  • To enhance Dmab distribution to bone by engineering a bispecific antibody targeting osteonectin (On).
  • To improve RANKL neutralization efficiency within the bone microenvironment.

Main Methods:

  • Reengineered Dmab by fusing it with single-chain variable fragments targeting osteonectin (On).
  • Assessed the bispecific antibody's (Dmab-FvOn) RANKL inhibitory activity in an osteoclast differentiation assay.
  • Administered Dmab-FvOn to mice to evaluate its bone localization.

Main Results:

  • Dmab-FvOn demonstrated comparable RANKL inhibitory activity to Dmab.
  • In vivo studies showed increased Dmab-FvOn localization at the bone endosteum, where osteonectin is abundant.
  • The engineered antibody enhances Dmab distribution within the bone microenvironment.

Conclusions:

  • Linking anti-RANKL antibodies with osteonectin-targeting moieties can improve therapeutic effector distribution in bone.
  • Further research is required to determine if Dmab-FvOn offers superior therapeutic efficacy and reduced toxicity.
Keywords:
SPARCanti-RANKLbispecific antibodybone-targetingdenosumabdisease site deliveryosteonectin

More Related Videos

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

9.8K
Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry11:20

Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry

Published on: March 29, 2018

8.1K

Related Concept Videos

Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.7K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.4K